Compare Neurocrine Biosciences Inc (NBIX) vs Taiwan Semiconductor Mfg. Co. Ltd. (TSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Taiwan Semiconductor Mfg. Co. Ltd. — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Taiwan Semiconductor Mfg. Co. Ltd. trades at $423.11 (market cap $1.88T). The key difference: Taiwan Semiconductor Mfg. Co. Ltd. is far larger — about 108× Neurocrine Biosciences Inc's market cap, and Taiwan Semiconductor Mfg. Co. Ltd. pays a 0.94% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | TSM | |
|---|---|---|
Market Cap | $17.40B | $1.88T |
Sector | Health | Technology |
52-Week High | $180.55 | $477.57 |
52-Week Low | $123.10 | $227.33 |
Enterprise Value | $16.49B | $1.81T |
Dividend Yield | — | 0.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% today, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 EPS of $1.94 beating expectations by 59%, revenue growth to $3.1B in 2026, and net income margin expanding to 21.55%. Recent news highlights executive appointments and positive clinical trial updates for crinecerfont, supporting growth prospects.
Outlook remains positive with 86% analyst buy ratings and a $196.08 consensus price target implying 13% upside. Key risks include execution of pipeline developments and integration of acquisitions. The stock's valuation at P/E 26.62 appears reasonable given earnings growth trajectory and strong profitability metrics.
TSM trades at $424.61, up 6.59% today, with strong fundamentals including 49.92% net income margin and 40.26% ROE. The stock shows bearish technical signals but has beaten earnings estimates for three consecutive quarters. Recent news highlights TSMC's plans to raise chipmaking prices by up to 10% in 2027, positioning the company to capitalize on AI infrastructure demand.
Analysts maintain strong bullish sentiment with a $547.50 consensus price target (72% buy ratings), though technical indicators suggest near-term caution. Key risks include competitive pressures and market volatility, but TSMC's dominant market position and pricing power provide solid long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Taiwan Semiconductor Mfg. Co. Ltd.
Taiwan Semiconductor Manufacturing Company, or TSMC, is the world's largest dedicated chip foundry, with over 57% market share in 2021 per Gartner. TSMC was founded in 1987 as a joint venture of Philips, the government of Taiwan, and private investors. It went public as an ADR in the U.S. in 1997. TSMC's scale and high-quality technology allow the firm to generate solid operating margins, even in the highly competitive foundry business. Furthermore, the shift to the fabless business model has created tailwinds for TSMC. The foundry leader has an illustrious customer base, including Apple, AMD and Nvidia, that looks to apply cutting-edge process technologies to its semiconductor designs.
Read more on TSM →
